Literature DB >> 20643911

Predicting utility for joint health states: a general framework and a new nonparametric estimator.

Alex Z Fu.   

Abstract

Measuring utility is important in clinical decision making and cost-effectiveness analysis because utilities are often used to compute quality-adjusted life expectancy, a metric used in measuring the effectiveness of health care programs and medical interventions. Predicting utility for joint health states has become an increasingly valuable research topic because of the aging of the population and the increasing prevalence of comorbidities. Although multiplicative, minimum, and additive estimators are commonly used in practice, research has shown that they are all biased. In this study, the authors propose a general framework for predicting utility for joint health states. This framework includes these 3 nonparametric estimators as special cases. A new simple nonparametric estimator, the adjusted decrement estimator, [U(ij) = U(min) - U(min) (1 - U(i) )(1 - U(j) )], is introduced under the proposed framework. When applied to 2 independent data sources, the new nonparametric estimator not only generated unbiased prediction of utilities for joint health states but also had the least root mean squared error and highest concordance when compared with other nonparametric and parametric estimators. Further research and validation of this new estimator are needed.

Mesh:

Year:  2010        PMID: 20643911     DOI: 10.1177/0272989X10374508

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  16 in total

1.  Valuation of depression co-occurring with a somatic condition: feasibility of the time trade-off task.

Authors:  Katerina Papageorgiou; Karin M Vermeulen; Fenna R M Leijten; Erik Buskens; Adelita V Ranchor; Maya J Schroevers
Journal:  Health Expect       Date:  2014-11-13       Impact factor: 3.377

2.  The impact of co-morbidity burden on preference-based health-related quality of life in the United States.

Authors:  Patrick W Sullivan; Vahram H Ghushchyan; Elizabeth A Bayliss
Journal:  Pharmacoeconomics       Date:  2012-05       Impact factor: 4.981

3.  Sourcing quality-of-life weights obtained from previous studies: theory and reality in Korea.

Authors:  SeungJin Bae; Eun Young Bae; Sang Hee Lim
Journal:  Patient       Date:  2014       Impact factor: 3.883

4.  Cost Effectiveness of Apixaban and Enoxaparin for the Prevention of Venous Thromboembolism After Total Knee Replacement in China.

Authors:  Xiaoyu Yan; Xiaohua Gu; Lei Zhou; Houweng Lin; Bin Wu
Journal:  Clin Drug Investig       Date:  2016-12       Impact factor: 2.859

Review 5.  Estimating Health State Utility Values for Comorbidities.

Authors:  Roberta Ara; John Brazier
Journal:  Pharmacoeconomics       Date:  2017-12       Impact factor: 4.981

6.  Joint Utility Estimators in Substance Use Disorders.

Authors:  Eve Wittenberg; Jeremy W Bray; Achamyeleh Gebremariam; Brandon Aden; Bohdan Nosyk; Bruce R Schackman
Journal:  Value Health       Date:  2016-11-17       Impact factor: 5.725

7.  Cost-effective screening for acute hepatitis C virus infection in HIV-infected men who have sex with men.

Authors:  Benjamin P Linas; Angela Y Wong; Bruce R Schackman; Arthur Y Kim; Kenneth A Freedberg
Journal:  Clin Infect Dis       Date:  2012-04-04       Impact factor: 9.079

8.  Measuring benefits of opioid misuse treatment for economic evaluation: health-related quality of life of opioid-dependent individuals and their spouses as assessed by a sample of the US population.

Authors:  Eve Wittenberg; Jeremy W Bray; Brandon Aden; Achamyeleh Gebremariam; Bohdan Nosyk; Bruce R Schackman
Journal:  Addiction       Date:  2015-12-17       Impact factor: 6.526

9.  Health Economic Analysis of Antiplatelet Therapy for Acute Coronary Syndromes in the Context of Five Eastern Asian Countries.

Authors:  Bin Wu; Ruoyan Gai Tobe; Yuchen Liu; Ben He
Journal:  Clin Drug Investig       Date:  2018-07       Impact factor: 2.859

10.  Economic evaluation of apixaban for the prevention of stroke in non-valvular atrial fibrillation in the Netherlands.

Authors:  Jelena Stevanović; Marjolein Pompen; Hoa H Le; Mark H Rozenbaum; Robert G Tieleman; Maarten J Postma
Journal:  PLoS One       Date:  2014-08-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.